amoeba SA Industrial greentech & biocontrol
A French industrial greentech company listed on Euronext Growth Paris developing natural, effective, and sustainable alternatives to conventional chemical products in agriculture and cosmetics, all built on a unique technology platform derived from the Willaertia magna C2c Maky amoeba.
amoeba SA Investor Relations Video Hub
All CEO & CFO video presentations from Amoéba SA filter by format below to find what you need.
Amoeba SA Elevator Pitch | Biocontrol, Cosmetics & Commercial Growth
CEO Jean-François Doucet explains how Amoéba is transitioning from technology development to commercial execution across the agricultural biocontrol and cosmetics markets.
Watch presentation
Industrial greentech & biocontrol
Amoéba is an industrial greentech company listed on Euronext Growth Paris. The Company develops natural, effective, and sustainable alternatives to conventional chemical products both in agriculture and cosmetics based on a unique technology platform derived from the amoeba Willaertia magna C2c Maky. After more than a decade of R&D, field validation, product authorisation, and industrial development, Amoéba is entering a phase focused on commercial execution alongside selected business partners.
A Unique Technology Platform
Amoéba has developed a proprietary industrial process enabling the cultivation of Willaertia magna at scale and the production of a non-living processed form containing a broad diversity of natural compounds. This know-how, protected by a strong intellectual-property portfolio, creates a significant technological lead and makes the platform very difficult to replicate underpinning the Group's ability to monetise the technology across more than one end-market.
Two Markets Demanding Innovation
The same technology platform addresses two large markets with strong demand for innovation. In agriculture, Amoéba develops biocontrol solutions to help farmers fight fungal diseases at a time when many conventional chemical solutions are being restricted or withdrawn from market. In cosmetics, the Company provides a natural active ingredient for skin care and well-ageing, designed for brands seeking innovative, scientifically supported, and natural ingredients. The Group has attracted leading international partners in both segments.
Business Model and Value Creation
Amoéba follows an asset-light industrial model, relying on selected CDMO partners to support scale-up and production rather than committing significant capital to in-house manufacturing. Combined with regulatory progress, commercial partnerships, and two complementary end-markets, this model positions the Company to move from technology validation toward broader market access and revenue generation.
Want your company
on seat11a?
Join Amoéba and 100+ listed companies reaching institutional investors through CEO and CFO video presentations.